This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 17126 results found since Jan 2013.
Review of Superficial Cryotherapy for the Treatment of Alopecia Areata
J Drugs Dermatol. 2023 Aug 1;22(8):802-809. doi: 10.36849/jdd.7431.ABSTRACTCryotherapy has recently been examined as a potential treatment for alopecia areata (AA). AA is classically managed with intralesional or systemic steroids but relapse rates among those with longstanding disease are high. This narrative review serves to describe the existing studies evaluating cryotherapy for the treatment of AA and examine studies comparing cryotherapy with intralesional steroid injection for the treatment of AA. A review of the literature from 1990 to 2022 was conducted looking for keywords such as “alopecia areata&r...
Source: Journal of Drugs in Dermatology - August 9, 2023 Category: Dermatology Authors: Michael Kaiser Najy Issa Marita Yaghi Joaquin J Jimenez Naiem T Issa Source Type: research
Off-Label Use of Baricitinib in Dermatology
J Drugs Dermatol. 2023 Aug 1;22(8):795-801. doi: 10.36849/jdd.7360.ABSTRACTThe current US Food and Drug Administration (FDA) indications for baricitinib include alopecia areata, rheumatoid arthritis, and COVID-19. However, increasing evidence indicates that baricitinib is effective in treating a variety of dermatological conditions. This review article comprehensively presents the available literature on this topic and will be of interest to practitioners in the field. These disorders may be broadly classified as connective tissue diseases, eczematous dermatoses, alopecias, vascular disorders, granulomatous diseases, neutr...
Source: Journal of Drugs in Dermatology - August 9, 2023 Category: Dermatology Authors: Asghar Shah Sara Yumeen Abrar Qureshi Elie Saliba Source Type: research
Review of Superficial Cryotherapy for the Treatment of Alopecia Areata
J Drugs Dermatol. 2023 Aug 1;22(8):802-809. doi: 10.36849/jdd.7431.ABSTRACTCryotherapy has recently been examined as a potential treatment for alopecia areata (AA). AA is classically managed with intralesional or systemic steroids but relapse rates among those with longstanding disease are high. This narrative review serves to describe the existing studies evaluating cryotherapy for the treatment of AA and examine studies comparing cryotherapy with intralesional steroid injection for the treatment of AA. A review of the literature from 1990 to 2022 was conducted looking for keywords such as “alopecia areata&r...
Source: Journal of Drugs in Dermatology - August 9, 2023 Category: Dermatology Authors: Michael Kaiser Najy Issa Marita Yaghi Joaquin J Jimenez Naiem T Issa Source Type: research
Ritlecitinib: First Approval
This article summarizes the milestones in the development of ritlecitinib leading to this first approval for severe alopecia areata.
Source: Drugs - August 9, 2023 Category: Drugs & Pharmacology Source Type: research
Diagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023)
AbstractAlopecia areata (AA) is a complex autoimmune disease manifesting as a chronic inflammatory disease characterized by non-scarring patches of hair loss over the face, scalp, and body. Several treatments have been proposed for AA, but none are curative nor achieve a state of remission. The present consensus statement aims to present the evidence- and experience-based recommendations on the diagnosis and management of AA in Saudi Arabia. The Ministry of Health in Saudi Arabia has opted to initiate a meeting of a multidisciplinary group to discuss and concede on this topic. Eight dermatology experts and clinical pharmac...
Source: Dermatology and Therapy - August 9, 2023 Category: Dermatology Source Type: research
Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
This pooled analysis aims to determine the efficacy of uptitration to baricitinib, 4 mg, for 24 weeks in patients who had previously not responded to baricitinib, 2 mg.
Source: JAMA Dermatology - August 9, 2023 Category: Dermatology Source Type: research
Diagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023)
AbstractAlopecia areata (AA) is a complex autoimmune disease manifesting as a chronic inflammatory disease characterized by non-scarring patches of hair loss over the face, scalp, and body. Several treatments have been proposed for AA, but none are curative nor achieve a state of remission. The present consensus statement aims to present the evidence- and experience-based recommendations on the diagnosis and management of AA in Saudi Arabia. The Ministry of Health in Saudi Arabia has opted to initiate a meeting of a multidisciplinary group to discuss and concede on this topic. Eight dermatology experts and clinical pharmac...
Source: Dermatology and Therapy - August 9, 2023 Category: Dermatology Source Type: research
Serum uric acid level in male patients with androgenetic alopecia: A prospective study in China
CONCLUSIONS: We found that AGA has a relationship with hyperuricemia, and the level of serum UA can decrease with the treatment of finasteride.PMID:37553022 | DOI:10.1016/j.amjms.2022.12.032
Source: The American Journal of the Medical Sciences - August 8, 2023 Category: General Medicine Authors: Hang Zhou Boyang Zhou Xiaoli Sun Fenglin Zhuo Jian Zhao Linfeng Li Source Type: research
This month in JAAD case reports: October 2023 —Central centrifugal cicatricial alopecia in Black men
Central centrifugal cicatricial alopecia (CCCA) is the leading cause of scarring alopecia in Black patients. Primarily affecting women of African ancestry, starting in their late 20s, it has rarely been described in men. Historically, it has been associated with certain hair care practices, such as the use of hot combs, relaxers, braids, weaves, or tight extension; yet, studies supporting these associations have failed to provide definitive evidence. More recently, a mutation in the gene that encodes peptidyl arginine deiminase, type III (PADI3), an enzyme that is involved in hair shaft formation, has been linked to CCCA.
Source: Journal of the American Academy of Dermatology - August 8, 2023 Category: Dermatology Authors: Brett Sloan Tags: This month in Source Type: research
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
AbstractTrastuzumab deruxtecan (T-DXd) —an antibody–drug conjugate targeting the human epidermal growth factor receptor 2 (HER2)—improved outcomes of patients with HER2-positive and HER2-low metastatic breast cancer. Guidance on monitoring and managing T-DXd–related adverse events (AEs) is an emerging unmet need as translating cl inical trial experience into real-world practice may be difficult due to practical and cultural considerations and differences in health care infrastructure. Thus, 13 experts including oncologists, pulmonologists and a radiologist from the Asia-Pacific region gathered to provide recommenda...
Source: Drug Safety - August 8, 2023 Category: Drugs & Pharmacology Source Type: research
This Month in JAAD Case Reports: October 2023 – Central Centrifugal Cicatricial Alopecia in Black Men
Source: Journal of the American Academy of Dermatology - August 8, 2023 Category: Dermatology Authors: Brett Sloan Source Type: research
Effect of Janus Kinase 3 Inhibitor on Sebaceous Gland Regeneration during Skin Wound Healing
CONCLUSION: These data showed that Jak3 signaling is a potent regulator to develop SGs. Jak3 inhibition did not decrease the number of sebocytes in SGs but decreased the area and volume of SG remodeling. Therefore, Jak3 inhibition may be a potential target for the treatment of SG hyperplasia and associated skin diseases.PMID:37550228 | DOI:10.5021/ad.22.204
Source: Annals of Dermatology - August 7, 2023 Category: Dermatology Authors: Won Tae Jo A Young Kim Hyun Goo Woo Hae Jun Song Eun Joo Baik Source Type: research
